Market capitalization | $26.17b |
Enterprise Value | $29.42b |
PER (TTM) P/E ratio | 38.47 |
EV/FCF (TTM) EV/FCF | 25.23 |
EV/Sales (TTM) EV/Sales | 3.57 |
P/S ratio (TTM) P/S ratio | 3.18 |
P/B ratio (TTM) P/B ratio | 2.77 |
Sales growth (TTM) Sales growth | 5.29% |
Turnover (TTM) Turnover | $8.23b |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
18 Analysts have issued a ICON Plc forecast:
18 Analysts have issued a ICON Plc forecast:
Mar '24 |
+/-
%
|
||
Net profit | 187 187 |
61%
61%
|
|
Depreciation and amortization | 161 161 |
3%
3%
|
|
Share compensation | 13 13 |
11%
11%
|
|
Operating cash flow | 327 327 |
86%
86%
|
|
Investments | 27 27 |
2%
2%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | 300 300 |
102%
102%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Stephen Cutler |
Employees | 41,100 |
Founded | 1989 |
Website | www.iconplc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.